Pamela Morris to United States
This is a "connection" page, showing publications Pamela Morris has written about United States.
Connection Strength
0.591
-
2019 Methodology for Heart House Roundtables: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019 08 27; 74(8):1116-1137.
Score: 0.070
-
2019 Methodology for Creating Expert Consensus Decision Pathways: A Report of the American College of Cardiology. J Am Coll Cardiol. 2019 08 27; 74(8):1138-1150.
Score: 0.070
-
Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease prevention. J Clin Lipidol. 2016 May-Jun; 10(3):458-61.
Score: 0.056
-
What the guidelines do not say: statin non-benefit groups. Curr Atheroscler Rep. 2015 Jan; 17(1):468.
Score: 0.051
-
Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol. 2014 Jul 15; 64(2):196-206.
Score: 0.049
-
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
Score: 0.022
-
Special Considerations for Healthy Lifestyle Promotion Across the Life Span in Clinical Settings: A Science Advisory From the American Heart Association. Circulation. 2021 12 14; 144(24):e515-e532.
Score: 0.020
-
Strategies for Promotion of a Healthy Lifestyle in Clinical Settings: Pillars of Ideal Cardiovascular Health: A Science Advisory From the American Heart Association. Circulation. 2021 12 14; 144(24):e495-e514.
Score: 0.020
-
Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels. JAMA Netw Open. 2021 10 01; 4(10):e2128817.
Score: 0.020
-
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 08 31; 78(9):960-993.
Score: 0.020
-
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 09 01; 76(9):1117-1145.
Score: 0.019
-
Association of Smokeless Tobacco Use With the Use of Other Illicit Drugs in the United States. Am J Med. 2021 01; 134(1):e15-e19.
Score: 0.019
-
Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
Score: 0.017
-
2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018 12 25; 72(25):3332-3365.
Score: 0.017
-
Another Article About E-Cigarettes: Why Should I Care? J Am Heart Assoc. 2018 07 14; 7(14).
Score: 0.016
-
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
Score: 0.016
-
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
Score: 0.016
-
2017 Focused Update of the 2016?ACC?Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in?the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017 Oct 03; 70(14):1785-1822.
Score: 0.015
-
Risk Factors for Mortality Among Individuals With Peripheral Arterial Disease. Am J Cardiol. 2017 Sep 01; 120(5):862-867.
Score: 0.015
-
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
Score: 0.015
-
Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016 11 22; 134(21):e468-e495.
Score: 0.014
-
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 07 05; 68(1):92-125.
Score: 0.014